MediWound (Nasdaq:MDWD) - Hisse Senedi Fiyatı, Haberler ve Analizler

MDWD Stoklara Genel Bakış

MDWD temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Kazançların yılda 56.2% oranında artması öngörülüyor

Analistler hisse senedi fiyatının 64.4% oranında artacağı konusunda hemfikir

Risk Analizi

Hissedarlar geçen yıl sulandırıldı

MediWound Ltd. Rakipler

Procaps Group

NasdaqGM:PROC

US$224.5m

Nektar Therapeutics

NasdaqCM:NKTR

US$219.1m

BioStem Technologies

OTCPK:BSEM

US$277.2m

biote

NasdaqGM:BTMD

US$184.7m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti MediWound
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$18.10
52 Haftanın En Yüksek Seviyesi	US$24.00
52 Haftanın En Düşük Seviyesi	US$7.45
Beta	0.83
11 Aylık Değişim	7.61%
3 Aylık Değişim	3.55%
1 Yıllık Değişim	120.19%
33 Yıllık Değişim	-28.17%
5 Yıllık Değişim	-13.81%
Halka arzdan bu yana değişim	-85.03%

Son Haberler & Güncellemeler

MediWound Is A Healthy Investment

Oct 29

Market Participants Recognise MediWound Ltd.'s (NASDAQ:MDWD) Revenues Pushing Shares 43% Higher

Jul 23

Recent updates

MediWound Is A Healthy Investment

Oct 29

Market Participants Recognise MediWound Ltd.'s (NASDAQ:MDWD) Revenues Pushing Shares 43% Higher

Jul 23

Analysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) First-Quarter Report

Jun 01

Revenues Tell The Story For MediWound Ltd. (NASDAQ:MDWD) As Its Stock Soars 25%

May 07

We're Hopeful That MediWound (NASDAQ:MDWD) Will Use Its Cash Wisely

Feb 28

Optimistic Investors Push MediWound Ltd. (NASDAQ:MDWD) Shares Up 26% But Growth Is Lacking

Feb 01

MediWound Ltd.'s (NASDAQ:MDWD) 26% Share Price Surge Not Quite Adding Up

Dec 18

MediWound Ltd. (NASDAQ:MDWD) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Sep 29

MediWound's NexoBrid for thermal burns in children gets EMA review

Sep 20

Need To Know: Analysts Just Made A Substantial Cut To Their MediWound Ltd. (NASDAQ:MDWD) Estimates

Aug 11

MediWound GAAP EPS of -$0.13 misses by $0.03, revenue of $4.67M misses by $0.61M

Aug 09

MediWound completes enrollment for interim assessment of mid-stage EscharEx study

Jun 09

Hissedar Getirileri

	MDWD	US Pharmaceuticals	US Pazar
7D	3.5%	-3.7%	0.5%
1Y	120.2%	22.6%	36.8%

Getiri vs. Endüstri: MDWD geçen yıl % 22.6 oranında getiri sağlayan US Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: MDWD geçen yıl % 36.8 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is MDWD's price volatile compared to industry and market?
MDWD volatility
MDWD Average Weekly Movement	7.5%
Pharmaceuticals Industry Average Movement	9.4%
Market Average Movement	6.1%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.0%

İstikrarlı Hisse Senedi Fiyatı: MDWD son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: MDWD 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2000	100	Ofer Gonen	www.mediwound.com

Bir biyofarmasötik şirketi olan MediWound Ltd. doku onarımı ve rejenerasyonu için yeni, biyo-terapötik ve cerrahi olmayan çözümler geliştirmekte, üretmekte ve Amerika Birleşik Devletleri, Avrupa ve uluslararası alanda ticarileştirmektedir. Derin kısmi ve tam kalınlıkta termal yanıkları olan yetişkinlerde ölü veya hasarlı bir doku olan eskarın giderilmesi için biyofarmasötik bir ürün olan NexoBrid'i yanık merkezlerine ve hastanelerin yanık ünitelerine pazarlamaktadır.

MediWound Ltd. Temel Bilgiler Özeti

MediWound'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
MDWD temel i̇stati̇sti̇kler
Piyasa değeri	US$195.23m
Kazançlar(TTM)	-US$19.97m
Gelir(TTM)	US$20.14m

9.7x

P/S Oranı

-9.8x

F/K Oranı

MDWD aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
MDWD gelir tablosu (TTM)
Gelir	US$20.14m
Gelir Maliyeti	US$17.47m
Brüt Kâr	US$2.67m
Diğer Giderler	US$22.64m
Kazançlar	-US$19.97m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.85
Brüt Marj	13.25%
Net Kâr Marjı	-99.17%
Borç/Özkaynak Oranı	0%

MDWD uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

MDWD Stoklara Genel Bakış

Ödüller

Risk Analizi

MediWound Ltd. Rakipler

NasdaqGM:PROC

US$224.5m

NasdaqCM:NKTR

US$219.1m

OTCPK:BSEM

US$277.2m

NasdaqGM:BTMD

US$184.7m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

MediWound Is A Healthy Investment

MediWound Ltd. Announces Phase II Head-To-Head Study Evaluating EscharEx®? vs. Collagenase in Patients with Venous Leg Ulcers

MediWound Ltd. Announces Positive Results from the U.S. NexoBrid Expanded Access Protocol (NEXT)

MediWound Ltd. to Report Q2, 2024 Results on Aug 14, 2024

MediWound Ltd. Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

Market Participants Recognise MediWound Ltd.'s (NASDAQ:MDWD) Revenues Pushing Shares 43% Higher

Recent updates

MediWound Is A Healthy Investment

MediWound Ltd. Announces Phase II Head-To-Head Study Evaluating EscharEx®? vs. Collagenase in Patients with Venous Leg Ulcers

MediWound Ltd. Announces Positive Results from the U.S. NexoBrid Expanded Access Protocol (NEXT)

MediWound Ltd. to Report Q2, 2024 Results on Aug 14, 2024

MediWound Ltd. Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

Market Participants Recognise MediWound Ltd.'s (NASDAQ:MDWD) Revenues Pushing Shares 43% Higher

MediWound Ltd. announced that it expects to receive $24.999994 million in funding from Mölnlycke Health Care AB and other investors

Analysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) First-Quarter Report

MediWound Ltd., Annual General Meeting, Jul 09, 2024

MediWound Ltd. to Report Q1, 2024 Results on May 29, 2024

Revenues Tell The Story For MediWound Ltd. (NASDAQ:MDWD) As Its Stock Soars 25%

Consensus EPS estimates fall by 25%, revenue upgraded

Full year 2023 earnings released: US$0.74 loss per share (vs US$3.93 loss in FY 2022)

MediWound Ltd. to Report Q4, 2023 Results on Mar 21, 2024

We're Hopeful That MediWound (NASDAQ:MDWD) Will Use Its Cash Wisely

Mediwound Ltd. Announces Positive Results in Head-To-Head Comparison of Escharex® Vs. Santyl® Within the Chronex Phase Ii Randomized Controlled Study

Optimistic Investors Push MediWound Ltd. (NASDAQ:MDWD) Shares Up 26% But Growth Is Lacking

Mediwound Announces That FDA Has Accepted for Review the Supplement to the Nexobrid BLA to Include Pediatric Patients with Severe Thermal Burns

Mediwound Ltd. Announces Publication of Escharex Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

MediWound Ltd.'s (NASDAQ:MDWD) 26% Share Price Surge Not Quite Adding Up

Third quarter 2023 earnings: EPS exceeds analyst expectations

Consensus EPS estimates upgraded to US$0.75 loss

MediWound Ltd. Appoints Shmulik Hess as Chief Operating Officer and Chief Commercial Officer, Effective December 1, 2023

MediWound Ltd. to Report Q3, 2023 Results on Nov 21, 2023

MediWound Ltd Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients

MediWound Ltd. (NASDAQ:MDWD) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

MediWound Ltd. Secures Additional U.S. Department of Defense Funding to Advance NexoBrid Development for the U.S. Army

New major risk - Shareholder dilution

MediWound Ltd. Announces U.S. Commercial Availability of NexoBrid®? for the Treatment of Severe Thermal Burns in Adults

High number of new and inexperienced directors

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 20% to US$27.25

MediWound Ltd. to Report Q2, 2023 Results on Aug 15, 2023

MediWound Ltd. Announces Commercial Launch of NexoBrid®? in Japan

Mediwound Ltd. Announces Positive Results in Its U.S. Phase I/Ii Study of Mw005 for the Treatment of Basal Cell Carcinoma

MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design

Consensus revenue estimates fall by 12%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

MediWound Ltd. to Report Q1, 2023 Results on May 30, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus estimates of losses per share improve by 10%

MediWound Ltd. Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults

Price target decreased to US$43.50

MediWound Announces Positive Results in U.S. Phase I/II Study of Mw005 for the Treatment of Basal Cell Carcinoma

MediWound Ltd Gains Marketing Approval of NexoBrid® in India

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

MediWound Ltd. to Report Q3, 2022 Results on Nov 15, 2022

High number of new directors

High number of new directors

MediWound Ltd. Announces Formation of Strategic Advisory Board

MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022

Price target increased to US$7.20

MediWound Ltd. Announces European Medicines Agency Validates for Review the Type Ii Variation

MediWound's NexoBrid for thermal burns in children gets EMA review

Consensus revenue estimates fall by 14%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Need To Know: Analysts Just Made A Substantial Cut To Their MediWound Ltd. (NASDAQ:MDWD) Estimates

Mediwound Ltd. Announces Management Changes